Group 1 - The core point of the article highlights that Chengyitong's stock price dropped by 5.28% to 24.24 CNY per share, with a trading volume of 174 million CNY and a turnover rate of 2.69%, resulting in a total market capitalization of 6.619 billion CNY [1] - Chengyitong, established on July 22, 2003, and listed on March 19, 2015, specializes in providing overall solutions for pharmaceutical and biopharmaceutical automation control systems, as well as the research, production, and sales of rehabilitation medical devices [1] - The revenue composition of Chengyitong includes 54.65% from control systems, 28.89% from rehabilitation medical devices, and 16.47% from system equipment and others [1] Group 2 - Longcheng Fund's Longcheng Consumption Value Mixed A (200006) fund is among the top ten circulating shareholders of Chengyitong, holding 2 million shares, which accounts for 0.77% of the circulating shares, with an estimated floating loss of approximately 2.7 million CNY [2] - The Longcheng Consumption Value Mixed A fund was established on April 6, 2006, with a latest scale of 516 million CNY, achieving a year-to-date return of 21.73% and a one-year return of 44.1% [2] - The fund manager, Long Yufei, has been in position for 8 years and 93 days, with the fund's total asset scale at 780 million CNY, achieving a best return of 61.42% and a worst return of -8.9% during his tenure [3] Group 3 - Longcheng Consumption Value Mixed A (200006) fund has Chengyitong as its ninth largest heavy stock, holding 2 million shares, which represents 4.74% of the fund's net value, with an estimated floating loss of around 2.7 million CNY [4]

Core Viewpoint - Hongbo Pharmaceutical's stock increased by 5.06% to 30.94 CNY per share, with a total market capitalization of 4.319 billion CNY as of November 24 [1] Company Overview - Hongbo Pharmaceutical, established on December 14, 2007, is located in the Pudong New Area of Shanghai and was listed on November 1, 2022 [1] - The company's main business includes drug discovery, pharmaceutical process research and development, and commercial production of raw material intermediates [1] - Revenue composition: Drug discovery accounts for 52.67%, commercial production 35.00%, process research and development 8.10%, and other activities 4.23% [1] Shareholder Information - Changcheng Fund's Changcheng Consumption Value Mixed A (200006) is among the top ten circulating shareholders of Hongbo Pharmaceutical, holding 1.6009 million shares, unchanged from the previous period, representing 2.08% of circulating shares [2] - The fund has an estimated floating profit of approximately 2.3854 million CNY as of today [2] Fund Performance - Changcheng Consumption Value Mixed A (200006) was established on April 6, 2006, with a current scale of 516 million CNY [2] - Year-to-date return is 14.39%, ranking 4459 out of 8209 in its category; one-year return is 6.92%, ranking 5776 out of 8129; and since inception, the return is 232.84% [2] Fund Manager Information - The fund manager of Changcheng Consumption Value Mixed A is Long Yufei, who has been in the position for 8 years and 40 days [3] - The total asset size of the fund is 843 million CNY, with the best return during the tenure being 61.42% and the worst return being -8.9% [3] Fund Holdings - Changcheng Consumption Value Mixed A (200006) has Hongbo Pharmaceutical as its sixth-largest holding, with 1.6009 million shares, accounting for 6.61% of the fund's net value [4] - The estimated floating profit for the fund from this holding is approximately 2.3854 million CNY [4]